Amundi Purchases 15,128 Shares of STAAR Surgical (NASDAQ:STAA)

Amundi grew its position in STAAR Surgical (NASDAQ:STAA) by 174.7% during the fourth quarter, HoldingsChannel reports. The firm owned 23,785 shares of the medical instruments supplier’s stock after buying an additional 15,128 shares during the period. Amundi’s holdings in STAAR Surgical were worth $550,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Quarry LP bought a new stake in shares of STAAR Surgical in the 3rd quarter valued at $50,000. Larson Financial Group LLC lifted its position in shares of STAAR Surgical by 78.3% during the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock valued at $181,000 after acquiring an additional 2,135 shares during the period. Illinois Municipal Retirement Fund lifted its position in shares of STAAR Surgical by 8.3% during the 4th quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier’s stock valued at $732,000 after acquiring an additional 2,318 shares during the period. FMR LLC lifted its position in shares of STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after acquiring an additional 3,136 shares during the period. Finally, Quest Partners LLC acquired a new position in shares of STAAR Surgical during the 3rd quarter valued at $128,000. 96.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

STAA has been the topic of a number of research reports. Piper Sandler dropped their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday. Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.29.

STAAR Surgical Price Performance

NASDAQ STAA opened at $17.92 on Friday. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The firm has a market cap of $883.90 million, a price-to-earnings ratio of -43.71 and a beta of 0.66. The company has a fifty day moving average price of $19.97 and a 200-day moving average price of $25.81.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock in a transaction that occurred on Thursday, March 20th. The stock was bought at an average price of $17.96 per share, for a total transaction of $1,952,611.20. Following the completion of the transaction, the insider now owns 12,182,995 shares in the company, valued at $218,806,590.20. This represents a 0.90 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders bought a total of 1,036,187 shares of company stock worth $17,239,548 in the last quarter. 1.00% of the stock is currently owned by corporate insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.